The effectiveness of patient monitoringwith serum tumor markers is improved when the patient's pretreatment baseline is established, regular serial testing is performed, and a clinicallysignificant change of the marker is determined on the basis of objectivecriteria. Attention must be directed to (a) ensuring long-term assay precision, (b) timing specimen collection to avoid misinterpretation of paradoxical increases (induced by chemotherapy, surgery, or radiation), (c) notingchanges in the production or clearance mechanisms of the marker, and (d) recognizing the variability of site-response in patients who have multiple locations of metastatic disease. Clinical decisions to alter therapy should not be based only on tumor marker measurements. In the absence of other clinical data, a tumor marker abnormality should be confirmed with serial samples collected at a time interval dictated by the half-life of the marker. Serial tumor marker testing can improve cancer patient care, especially when effective salvagetherapiesare available.
Results
Colorectai Cancer Figure l#{192} shows the CEA pattern of a patient with colorectal cancer with liver metastasis who on the day of surgery had a high CEA value. After The darkened area in the rectangular icon Is a semiquantitative volumeassessment of the lung metastasis. GW, chest wall; FAG, 5FU and adflamycln chemotherapy; PR, partialremission was no change in the lung lesion. By month 11, the lung lesion showed a significant response, but the chest wall lesion had now progressed.
A treatment change to tamoxifen resulted in a second partial remission of the chest wall lesion.
These CEA patterns from breast cancer patients show that increases in the serum tumor marker accurately reflect disease recurrence.
Similarly, decreases in the marker after therapy can reflect the efficacy of treatment. Transient increases due to cytotoxic drugs and hormonal agents must be recognized as such, to prevent misinterpretation as false-positive changes. However, not all patients will benefit from tumor marker monitoring because some tumors will produce insignificant amounts of the marker. However, even under ideal monitoring conditions, the tumor marker change may not be the earliest sign of change in the course of the disease; the marker production capability of the tumor must also be considered. When properly used, serial tumor marker testing can improve cancer patient care.
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